Pathomorphological and microbiological analysis of an epoxy-treated bioprosthetic heart valve functioning for 25 years in a patient with rheumatic heart disease: a case report
https://doi.org/10.15825/1995-1191-2025-1-183-187
Abstract
Bioprosthetic heart valves (BHVs) rarely last longer than 20 years due to the development of degenerative changes in their leaflets. We present a detailed pathomorphological description of KemCor, an epoxy-treated BHV that was removed from the mitral position 25 years after implantation. Literature review shows that this is the longest recorded lifespan of an epoxy-treated implant.
About the Authors
A. E. Kostyunin
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Alexander Kostyunin
6, Bul’var Barbarasha, Kemerovo, 650002 Phone: (900) 108-10-97
T. V. Glushkova
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
T. N. Akentyeva
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
E. A. Ovcharenko
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Kemerovo
References
1. Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017; 38 (28): 2183–2191. doi: 10.1093/eurheartj/ehx141.
2. Shetty R, Pibarot P, Audet A, Janvier R, Dagenais F, Perron J et al. Lipid-mediated inflammation and degeneration of bioprosthetic heart valves. Eur J Clin Invest. 2009; 39 (6): 471–480. doi: 10.1111/j.1365-2362.2009.02132.x.
3. Sakaue T, Koyama T, Nakamura Y, Okamoto K, Kawashima T, Umeno T et al. Bioprosthetic valve deterioration: accumulation of circulating proteins and macrophages in the valve interstitium. JACC Basic Transl Sci. 2023; 8 (7): 862–880. doi: 10.1016/j.jacbts.2023.01.003.
4. Barbarash LS, Zhuravleva IYu. Bioprosthetic heart valve evolution: two decades of advances and challenges. Complex Issues of Cardiovascular Diseases. 2012; 1: 4–11. (in Russ.). doi: 10.17802/2306-1278-2012-1-4-11.
5. Mukhamadiyarov RA, Rutkovskaia NV, Milto IV, Sidopova OD, Kudryavtseva YuA, Barbarash LS. Investigation of the structure of a functionally intact xenopericardial bioconduit after long-term implantation. Arkhiv Patologii. 2017; 79 (5): 25–33. (In Russ.). doi: 10.17116/patol201779525-33.
6. Mukhamadiyarov RA, Rutkovskaya NV, Sidorova OD, Barbarash LS. Cellular composition of calcified bioprostheti c heart valves. Annals of the Russian Academy of Medical Sciences. 2015; 70 (6): 662–668. (In Russ.). doi: 10.15690/vramn560.
7. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021; 143 (5): e72–e227. doi: 10.1161/CIR.0000000000000923.
8. Kubota S, Wakasa S, Ooka T, Tachibana T, Shiiya N, Matsui Y. A case of Carpentier-Edwards pericardial bioprosthesis in mitral position explanted 22 years after implantation. J Artif Organs. 2010; 13 (1): 48–50. doi: 10.1007/s10047-010-0483-2.
9. Koizumi S, Fukunaga N, Ikeda T, Koyama T. A case of an explanted 26-year-old Carpentier-Edwards supra-annular valve in the tricuspid position. J Cardiol Cases. 2016; 15 (1): 36–38. doi: 10.1016/j.jccase.2016.10.003.
Supplementary files
Review
For citations:
Kostyunin A.E., Glushkova T.V., Akentyeva T.N., Ovcharenko E.A. Pathomorphological and microbiological analysis of an epoxy-treated bioprosthetic heart valve functioning for 25 years in a patient with rheumatic heart disease: a case report. Russian Journal of Transplantology and Artificial Organs. 2025;27(1):183-187. https://doi.org/10.15825/1995-1191-2025-1-183-187
Views:
101
Email this article 